JP2009531404A5 - - Google Patents

Download PDF

Info

Publication number
JP2009531404A5
JP2009531404A5 JP2009502206A JP2009502206A JP2009531404A5 JP 2009531404 A5 JP2009531404 A5 JP 2009531404A5 JP 2009502206 A JP2009502206 A JP 2009502206A JP 2009502206 A JP2009502206 A JP 2009502206A JP 2009531404 A5 JP2009531404 A5 JP 2009531404A5
Authority
JP
Japan
Prior art keywords
unsubstituted
substituted
alkyl
carboaryl
aliphatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009502206A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009531404A (ja
JP5654748B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2007/001105 external-priority patent/WO2007110629A1/en
Publication of JP2009531404A publication Critical patent/JP2009531404A/ja
Publication of JP2009531404A5 publication Critical patent/JP2009531404A5/ja
Application granted granted Critical
Publication of JP5654748B2 publication Critical patent/JP5654748B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009502206A 2006-03-29 2007-03-28 タンパク質凝集の阻害物質 Expired - Fee Related JP5654748B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78670006P 2006-03-29 2006-03-29
US60/786,700 2006-03-29
PCT/GB2007/001105 WO2007110629A1 (en) 2006-03-29 2007-03-28 Inhibitors of protein aggregation

Publications (3)

Publication Number Publication Date
JP2009531404A JP2009531404A (ja) 2009-09-03
JP2009531404A5 true JP2009531404A5 (enExample) 2010-05-13
JP5654748B2 JP5654748B2 (ja) 2015-01-14

Family

ID=38068838

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009502206A Expired - Fee Related JP5654748B2 (ja) 2006-03-29 2007-03-28 タンパク質凝集の阻害物質

Country Status (13)

Country Link
US (3) US8263589B2 (enExample)
EP (1) EP2004155B1 (enExample)
JP (1) JP5654748B2 (enExample)
CN (2) CN101460157B (enExample)
AU (1) AU2007231126B2 (enExample)
CA (1) CA2645946C (enExample)
DK (1) DK2004155T3 (enExample)
ES (1) ES2667002T3 (enExample)
MY (1) MY153198A (enExample)
PL (1) PL2004155T3 (enExample)
PT (1) PT2004155T (enExample)
SI (1) SI2004155T1 (enExample)
WO (1) WO2007110629A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5186212B2 (ja) 2004-09-23 2013-04-17 ウィスタ ラボラトリーズ リミテッド メチルチオニニウム塩化物(mtc)などのジアミノフェノチアジニウム化合物を化学合成および精製する方法
DK2004155T3 (en) 2006-03-29 2018-04-30 Wista Lab Ltd PROTEIN AGGREGATION INHIBITORS
CN104119294B (zh) 2006-03-29 2018-10-30 维斯塔实验室有限公司 3,7-二氨基-10h-吩噻嗪化合物的制备方法
FR2903696B1 (fr) 2006-07-12 2011-02-11 Provence Technologies Procede de purification de composes diaminophenothiazium
AU2008265045B2 (en) * 2007-06-19 2014-02-27 Taurx Therapeutics Management Ltd. Phenothiazine compounds for treating Mild Cognitive Impairment
PT2954932T (pt) * 2007-10-03 2018-12-12 Wista Lab Ltd Utilização terapêutica de diaminofenotiazinas
AU2016202982B2 (en) * 2009-09-24 2017-09-21 TauRx Therapeutics Management Ltd Crystalline methylthionium chloride (methylene blue) hydrates
KR20170061177A (ko) * 2009-09-24 2017-06-02 위스타 레보레이토리스 리미티드 결정질 메틸티오니늄 클로라이드(메틸렌 블루) 수화물
US8785434B2 (en) 2010-04-30 2014-07-22 Prosetta Antiviral Inc. Antiviral compounds
US8828986B2 (en) 2011-04-20 2014-09-09 Prosetta Antiviral Inc. Antiviral compounds
WO2012106363A2 (en) 2011-01-31 2012-08-09 Intellect Neurosciences Inc. Treatment of tauopathies
KR101888713B1 (ko) * 2011-02-11 2018-08-14 위스타 레보레이토리스 리미티드 페노티아진 디아미늄 염 및 이의 용도
CN102690244A (zh) * 2011-03-22 2012-09-26 中国科学院上海生命科学研究院 调节α-突触核蛋白积聚的物质及其制药用途
GB201317702D0 (en) * 2013-10-07 2013-11-20 Wista Lab Ltd Methods of chemical synthesis of diaminophenothiazinium compounds including methylthioninium chloride (MTC)
EP3207925A1 (en) * 2016-02-22 2017-08-23 Universität Wien Compound for use in the prevention and treatment of neurodegenerative diseases
JP7033073B2 (ja) * 2015-11-30 2022-03-09 ウニヴェルシテート・ウィーン 神経変性疾患の予防及び治療において使用するための化合物
CN106046027B (zh) * 2016-06-30 2019-03-05 广东工业大学 一种含吡咯并吩噻嗪-1,3-二酮衍生物及其制备方法与应用
PL3487505T3 (pl) 2016-07-25 2023-10-09 Wista Laboratories Ltd. Podawanie i dawkowanie diaminofenotiazyn
EP3589616A1 (en) 2017-02-28 2020-01-08 Universitat Autònoma de Barcelona (nitro-phenyl)-nitropyridine compounds for treating synucleinopathies
FR3063495B1 (fr) * 2017-03-02 2019-04-05 Provepharm Life Solutions Procede de preparation de l’iodure de 3,7-bis(dimethylamino)phenothiazine-5-ylium
US11358942B2 (en) 2017-06-05 2022-06-14 Board Of Trustees Of Michigan State University Substituted phenothiazines as proteasome activators
WO2019025424A1 (en) 2017-08-04 2019-02-07 Universitat Autonoma De Barcelona COMPOUNDS FOR TREATING SYNUCLEINOPATHIES
US12071649B1 (en) 2017-12-03 2024-08-27 Nitrase Therapeutics, Inc. Identification of modulators of nitration and therapeutic uses thereof
WO2019161917A1 (en) 2018-02-23 2019-08-29 Universitat Autonoma De Barcelona 4-substituted 1-ethenylsulfonyl-2-nitrobenzene compounds for treating synucleinopathies
BR112021000802A2 (pt) 2018-07-26 2021-04-13 Wista Laboratories Ltd. Dosagem otimizada de diaminofenotiazinas em populações
CN113874078B (zh) 2019-04-05 2025-05-06 Tauc3生物制品有限公司 抗tauc3抗体及其应用
MY209608A (en) * 2019-04-10 2025-07-24 Genting Taurx Diagnostic Centre Sdn Bhd Adaptive neurological testing method
KR20220104000A (ko) * 2019-11-19 2022-07-25 모다크 게엠베하 알파-시누클레인의 응집과 관련된 질병의 진단, 치료 및 예방을 위한 신규한 화합물
CA3257856A1 (en) 2022-05-31 2023-12-07 Wista Laboratories Ltd. TREATMENT OF NEURODEGENERATIVE DISORDERS USING COMPOUNDS CONTAINING METHYLTHIONINIUM (MT)
KR20250154422A (ko) 2023-03-03 2025-10-28 타우알엑스 쎄라퓨틱스 매니지먼트 리미티드 미세혈관 뇌질환 치료를 위한 디아미노페노티아진
WO2024263638A2 (en) * 2023-06-20 2024-12-26 Yeefan Med Inc Pharmaceutical composition and uses thereof
GB202500018D0 (en) 2025-01-02 2025-02-19 Wista Lab Ltd Long term dosing of neurodegenerative disorders utilising methylthioninium (mt) containing compounds

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE569430A (enExample) 1957-07-17
US4309255A (en) * 1980-09-10 1982-01-05 International Business Machines Corporation Electrochromic recording paper
US4622395A (en) * 1984-10-01 1986-11-11 Minnesota Mining And Manufacturing Company Phenoxazine and phenothiazine dyes and leuco forms thereof
US4647525A (en) * 1984-10-01 1987-03-03 Minnesota Mining And Manufacturing Company Stabilized leuco phenazine dyes and their use in an imaging system
GB8724412D0 (en) 1987-10-19 1987-11-25 Medical Res Council Protein
US5571666A (en) 1988-10-28 1996-11-05 Oklahoma Medical Research Foundation Thiazine dyes used to inactivate HIV in biological fluids
US5220009A (en) * 1990-05-03 1993-06-15 Yeda Research And Development Company Limited Phenothiazinium salts and their use for disinfecting aqueous effluents
JPH0725786A (ja) 1990-05-16 1995-01-27 Univ Rockefeller アルツハイマー病を伴うアミロイドーシスの治療
WO1993003369A1 (en) 1991-08-01 1993-02-18 Voorheis Paul H Diagnostic method for alzheimer's disease
WO1993003177A1 (en) 1991-08-09 1993-02-18 Massachusetts Institute Of Technology Novel tau/neurofilament protein kinases
WO1993011231A1 (en) 1991-12-06 1993-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Tools for the diagnosis and treatment of alzheimer's disease
JPH06289015A (ja) 1993-03-30 1994-10-18 Sunstar Inc フェノチアジン系色源体安定化組成物
GB9316727D0 (en) 1993-08-12 1993-09-29 Inst Of Psychiatry Models of alzheimers's disease
GB9317193D0 (en) 1993-08-18 1993-10-06 Zeneca Ltd Method
WO1996004915A1 (en) 1994-08-08 1996-02-22 Albert Einstein College Of Medicine Of Yeshiva University Methods for treating and/or preventing alzheimer's disease using phenothiazines and/or thioxanthenes
DE4430091A1 (de) 1994-08-25 1996-02-29 Bayer Ag Verwendung von N-substituierten Phenothiazinen
GB9506197D0 (en) * 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
US5804601A (en) 1995-04-10 1998-09-08 Takeda Chemical Industries, Ltd. Aromatic hydroxamic acid compounds, their production and use
US5693638A (en) * 1996-02-23 1997-12-02 Myers; Daniel Method of treating a migraine headache
US6333322B1 (en) * 1996-03-13 2001-12-25 Eisai Co., Ltd. Nitrogen-containing tricyclic compounds and drugs containing the same
WO1999062548A1 (en) 1998-06-01 1999-12-09 Advanced Research And Technology Institute Methods and compositions for diagnosing tauopathies
FR2788436A1 (fr) 1999-01-14 2000-07-21 Pf Medicament Composition d'un derive de phenothiazine
WO2001053340A2 (en) 2000-01-21 2001-07-26 Pharmacia & Upjohn Company Transgenic mouse model of human neurodegenerative disease
GB0017060D0 (en) * 2000-07-11 2000-08-30 Hunter Fleming Ltd Production, stabilisation and use of reduced forms of pharmaceutical compounds
GB0100119D0 (en) 2001-01-03 2001-02-14 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0101049D0 (en) * 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
AU2002250117B2 (en) * 2001-03-15 2007-11-29 Cognitive Clarity Inc. Proanthocyanidins for the treatment of amyloid and alpha-synuclein diseases
GB0106953D0 (en) * 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
US20020197258A1 (en) * 2001-06-22 2002-12-26 Ghanbari Hossein A. Compositions and methods for preventing protein aggregation in neurodegenerative diseases
GB0117326D0 (en) 2001-07-16 2001-09-05 Univ Aberdeen Napthoquinone-type inhibitors of protein aggregation
US20030217370A1 (en) 2002-05-16 2003-11-20 Giasson Benoit I. Transgenic animal expressing alpha-synuclein and uses thereof
JP3867639B2 (ja) * 2002-07-31 2007-01-10 株式会社デンソー 混成集積回路装置
US6953974B2 (en) 2003-08-26 2005-10-11 Texas Instruments Incorporated EEPROM device and method for providing lower programming voltage
GB0322756D0 (en) 2003-09-29 2003-10-29 Univ Aberdeen Methods of chemical synthesis
BRPI0416928A (pt) 2003-11-28 2007-01-16 Photopharmica Ltd desenvolvimento de derivados biologicamente ativos de azul de metileno
DE602005016537D1 (de) * 2004-03-31 2009-10-22 Anges Mg Inc Testverfahren zur identifizierung eines kandidatenarzneistoffs
GB0420963D0 (en) 2004-09-21 2004-10-20 Reneuron Ltd Hepatocyte
WO2006032879A2 (en) 2004-09-23 2006-03-30 Wista Laboratories Ltd. Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (mtc)
JP5186212B2 (ja) * 2004-09-23 2013-04-17 ウィスタ ラボラトリーズ リミテッド メチルチオニニウム塩化物(mtc)などのジアミノフェノチアジニウム化合物を化学合成および精製する方法
WO2006122546A1 (de) 2005-05-18 2006-11-23 Forschungsverbund Berlin E.V. Nicht-peptidische inhibitoren der akap-pka-wechselwirkung
US20070116757A1 (en) * 2005-11-08 2007-05-24 Collegium Pharmaceutical, Inc. Methylene Blue Derivatives
CN104119294B (zh) 2006-03-29 2018-10-30 维斯塔实验室有限公司 3,7-二氨基-10h-吩噻嗪化合物的制备方法
DK2004155T3 (en) 2006-03-29 2018-04-30 Wista Lab Ltd PROTEIN AGGREGATION INHIBITORS

Similar Documents

Publication Publication Date Title
ES2667002T3 (es) Inhibidores de la agregación de proteínas
CN110997068B (zh) 用于成像和放射疗法的经放射标记的荧光parp抑制剂
JP2010530403A5 (enExample)
JP2009528271A5 (enExample)
JP2020526534A5 (enExample)
CN110123820B (zh) 精氨酸酶抑制剂及其使用方法
ES2759312T3 (es) Compuestos de aminocarbonilcarbamato
JP2010529088A5 (enExample)
RU2600793C2 (ru) Новый режим приема n-гидрокси-4-{2-[3-(n, n-диметиламинометил)бензофуран-2-илкарбониламино]этокси}бензамида
WO2004035522A1 (ja) プリオン蛋白蓄積性疾患の診断プローブおよび治療薬ならびにプリオン蛋白の染色剤
JP2015536986A5 (enExample)
JP2012511560A5 (enExample)
CN102083773A (zh) {f-19}标记的l-谷氨酸和l-谷氨酰胺衍生物(ⅲ)、其用途和制备方法
JP6987840B2 (ja) Ido1酵素イメージングのための放射性リガンド
JP2014532728A5 (enExample)
JP2010520276A5 (enExample)
JP2006510658A5 (enExample)
JP2024081755A (ja) Tspo結合剤
JP2020515523A5 (enExample)
JP2007532649A5 (enExample)
TWI287986B (en) Use of Epothilones for the treatment of the carcinoid syndrome
CN114945570A (zh) 雌激素受体调节剂的盐和形式
JP6450678B2 (ja) 新規な化合物およびその使用
JP2006510632A5 (enExample)
JP2022502378A5 (enExample)